NEW YORK (GenomeWeb) – While T2 Biosystems has been focused in recent months on ramping up its sales efforts around the recently approved sepsis fungal pathogen diagnostic T2Candida, the company is also planning for a December start of a clinical study for a complementary sepsis bacteria test.

The two tests are expected to be used in conjunction, enabling clinicians to identify nearly all the pathogens that cause sepsis infections, including ones that typically do not respond to first-line treatment.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.